Girls enjoying the sunset. (*Image for illustration only, patient identity protected for privacy.)*

For most teenagers, turning 18 is a time filled with dreams, school, friendships, and plans for the future.

But for Mary (pseudonym), an 18-year-old girl from Chongqing, China, much of her childhood and teenage years were defined by hospital visits, blood transfusions, and medications.

Diagnosed with transfusion-dependent beta thalassemia (TDT) before her first birthday, Mary spent 16 years relying on regular red blood cell transfusions to survive.

In 2026, a new chapter began. Through personalized gene therapy, Mary successfully achieved hematopoietic recovery and became free from regular transfusions, offering new hope for patients living with severe inherited blood disorders.

A Childhood Defined by Blood Transfusions

Mary was diagnosed with beta thalassemia major when she was only 11 months old.

Because of persistent paleness, her parents brought her to the hospital for evaluation. After medical testing, she was diagnosed with beta thalassemia major, a severe inherited blood disorder caused by mutations affecting hemoglobin production.

Hemoglobin is the protein inside red blood cells responsible for carrying oxygen throughout the body. In people with beta thalassemia, genetic mutations prevent the body from producing enough functional hemoglobin, leading to chronic anemia.

For Mary, this meant her body couldn’t produce enough healthy red blood cells on its own. From infancy, her life followed a strict routine:

Blood transfusions approximately every 20 days: Before each transfusion, her hemoglobin level often remained just above 90 g/L. After transfusion, it could increase to around 120 g/L.
Long-term iron chelation therapy: Because repeated transfusions can cause iron accumulation in the body, Mary began iron removal treatment at around 2–3 years old. She received medications including deferiprone and deferasirox.
Years of hospital visits: The cycle of transfusions and iron management continued for approximately 16 years.

Although these treatments helped maintain her health, they couldn’t correct the underlying genetic cause of her disease.

Searching for a Long-Term Solution: The Promise of Gene Therapy

Two years ago, Mary and her family learned about advances in gene therapy for beta thalassemia.

Traditional treatment options for severe beta thalassemia include regular transfusions, iron chelation therapy, and allogeneic hematopoietic stem cell transplantation (HSCT).

However, each approach has limitations:

Regular transfusions can manage anemia but do not address the genetic defect. Over time, iron overload caused by repeated transfusions may damage important organs, including the heart and liver.

Allogeneic stem cell transplantation can potentially cure beta thalassemia, but many patients face challenges finding a fully matched donor. In addition, transplantation carries risks such as graft-versus-host disease (GVHD), immune complications, and the need for long-term immunosuppressive medications.

Gene therapy offers a different approach. Instead of using donor cells, gene therapy uses the patient’s own hematopoietic stem cells. These cells are collected from the patient, genetically modified outside the body to restore functional gene expression, and then returned after conditioning treatment. Because the cells come from the patient, this approach avoids donor matching challenges and eliminates the risk of graft-versus-host disease. For eligible patients, gene therapy represents a shift from lifelong disease management toward a potential one-time treatment approach.

After comprehensive evaluation, Mary was considered a suitable candidate for gene therapy.

A multidisciplinary team from the hematology department, bone marrow transplant unit, and cell and gene therapy center at the hospital in Guangzhou began preparing her personalized treatment plan.

Medical Team Behind the Treatment

Mary’s beta thalassemia gene therapy was led by Dr. Huang Jinqi, a hematology specialist with expertise in hematologic diseases, stem cell transplantation, and cell and gene therapy. As part of the multidisciplinary team at the hospital in Guangzhou, Dr. Huang played a key role in patient evaluation, treatment planning, stem cell collection, conditioning therapy, infusion, and post-treatment management. Through close collaboration among hematologists, transplant specialists, and cell therapy experts, the team carefully guided Mary through each stage of this complex treatment process.

To help international patients access advanced hematology treatments in China, Dr. Huang and his medical team collaborate with Harmonia. Harmonia provides medical coordination, treatment communication support, and assistance throughout the patient journey, helping connect patients with experienced specialists and innovative therapies.

Learn More About Harmonia.

A Personalized Gene Therapy Journey

Step 1: Collecting Mary’s “Stem Cell Seeds”

The first step was collecting Mary’s own hematopoietic stem cells.

In October 2025, she received mobilization therapy to encourage stem cells from her bone marrow to move into the bloodstream.

Dr. Huang and his team then used a blood cell separation system to collect these valuable stem cells.

The collection process was performed twice to obtain enough cells for treatment.

Step 2: Genetic Modification Outside the Body

After collection, Mary’s stem cells were sent to a specialized gene therapy facility.

Using gene engineering technology, scientists introduced a functional gene into her hematopoietic stem cells to correct the genetic defect responsible for her beta thalassemia.

After quality testing confirmed that the modified cells met treatment standards, the genetically modified stem cells were frozen and prepared for reinfusion.

Step 3: Preparing Her Body for the Modified Cells

On March 22, 2026, Mary was admitted to the hospital to begin conditioning treatment before stem cell infusion. This preparation step helps create space in the bone marrow so that the modified stem cells can successfully establish themselves. She received a conditioning regimen using:

Fludarabine
Total marrow irradiation (TMI)

The process went smoothly.

On March 29, 2026, Mary received her genetically modified stem cells. Approximately 30 mL of cryopreserved modified stem cells were rapidly thawed in a 40°C water bath and infused back into her body in two separate infusions. The total dose was approximately:

9.78 × 10⁶ CD34+ cells/kg

(CD34+ cells are a key marker used to identify hematopoietic stem cells.)

A New Beginning: Successful Engraftment and Freedom From Transfusions

The recovery period after gene therapy required close monitoring.

During treatment, Mary experienced complications including diarrhea and fever. However, the medical team responded quickly and successfully managed these issues. Encouraging signs soon appeared.

Day +10 after infusion: Platelet engraftment was achieved.
Day +13 after infusion: Neutrophil engraftment was confirmed.

These milestones showed that the genetically modified stem cells had successfully settled in her bone marrow and started producing healthy blood cells.

On April 22, 2026, Mary was discharged from the hospital. At discharge:

Her hemoglobin level had increased to 132 g/L
She no longer required regular blood transfusions

Mary's follow-up visits continued to show steady recovery. After 16 years of living with the cycle of transfusions and iron chelation therapy, Mary finally returned to life as a normal student.

💡 Explore More Success Stories at Harmonia.

Reflections From Dr. Huang Jinqi

As a physician, witnessing Mary overcome 16 years of challenges caused by beta thalassemia and begin a new chapter of life has been deeply meaningful. Her journey reminds us once again of several important lessons:

The Promise of Precision Medicine:

Gene therapy is no longer just a concept from science fiction. It is steadily moving from research laboratories into clinical practice, bringing new possibilities for patients with inherited disorders like beta thalassemia and offering hope for long-term disease control or even a potential cure.

The Power of Teamwork:

From the initial patient evaluation and stem cell mobilization to cell collection, genetic modification, conditioning treatment, infusion, and post-treatment care, every step of gene therapy requires careful coordination. Each part of the process is critical, and success depends on the dedication, expertise, and collaboration of a multidisciplinary medical team.

Hope, Courage, and the Will to Keep Fighting:

For 16 years, Mary and her family never gave up hope. Their courage and willingness to pursue innovative treatment were essential parts of this journey. Their trust and perseverance remind us that advances in medicine are made possible not only by technology, but also by the determination of patients and their families.

Looking Ahead: A Future Beyond Transfusions

Every patient is different, and not everyone with beta thalassemia will be eligible for gene therapy. Eligibility depends on multiple factors, including disease status, overall health, and treatment evaluation.

However, Mary’s experience demonstrates the transformative potential of advanced cell and gene therapies.

As technology continues to advance, more patients with inherited blood disorders may have opportunities to move beyond lifelong transfusions and toward healthier, more independent lives.

For Mary, her 18th year became more than a birthday milestone.

It became the beginning of a new life.

Explore Gene Therapy Options for Beta Thalassemia

If you or your family are exploring advanced treatment options for transfusion-dependent beta thalassemia, Harmonia can help you connect with experienced hematology specialists, understand potential treatment pathways, and receive support throughout your medical journey.

Contact Harmonia for a Medical Consultation

Disclaimer: This patient story is shared for educational and informational purposes only. Individual treatment outcomes vary, and gene therapy is not suitable for every patient. Treatment decisions should be made after a comprehensive evaluation by qualified healthcare professionals. Harmonia does not provide medical diagnosis or guarantee treatment outcomes, but helps international patients access medical information and connect with appropriate specialists.

Medical Review & Editorial Information:

Written by Harmonia Content Team

Medically reviewed by Dr. Huang Jinqi, Deputy Chief Physician, Department of Hematology.

Clinical expertise: Beta Thalassemia | HSCT | Cell & Gene Therapy

加载中…

提交资料，申请专家病例评估